Ranbaxy in co-marketing agreement with Ferring of Switzerland
10 Jan 2006
![](ranbaxy_logo1.gif)
Desmopressin, an orginal research product of Ferring International, is available in tables and sprays, and is currently marketed by the company's Indian subsidiary. This new co-marketing arrangement will leverage Ranbaxy's marketing and distribution network and will be sold under the brand name Adiuretin.
Commenting on the development, Mr. Sanjeev Dani Regional Director- India & Middle East of the Company said,
"This is a strategic move by Ranbaxy to in-license differentiated products for the Indian market. In a short span of 3 years Ranbaxy has become a leader in the urology segment and this agreement further helps to consolidate out position as a provider of trusted, high quality medicines to the India market," commented Sanjeev Dani, regional director, India and Middle East, Ranbaxy.